Antibody production and plasmablast survival crucially depend on interleukin 6 (IL-6), which, in fact, is markedly increased in the serum and cerebrospinal fluid (CSF) of patients with NMOSD in comparison to healthy controls and, importantly, patients with MS [17, 18]. This evidence concerns the gene IL6 and myeloid sarcoma.